Skip to main content
Clinical Trials/NCT05131412
NCT05131412CompletedNot Applicable

Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation: a a Retrospective Cohort Study

Guangzhou Women and Children's Medical Center1 site in 1 country107 target enrollmentStarted: August 8, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
107
Locations
1
Primary Endpoint
overall cure rate

Study Overview

Brief Summary

The aim of this study is to determine whether mesenchymal stromal cell (MSC) treatment contribute to the good prognosis in patients with transplant-related complication, pneumonia post hematopoietic stem cell transplantation (HSCT).

Detailed Description

Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most hematologic disorders and malignancies. Despite the improved survival attributed to advances in HSCT including transplantation techniques and supportive care, transplant-related pneumonia (severe pneumonia in particular) remains the leading cause of death for most HSCT patients and a major challenge for clinicians.

Mesenchymal stromal cells (MSCs), a form of multipotent cells, have been applied in therapy for various intractable disorders. MSC exerts its therapeutic effect through various biological functions including immunoregulation, tissue repairing, self-renew and differentiating into various cell lines. The American Thoracic Society has also suggested MSCs as a cell therapy agent for lung diseases. However, MSC therapy for pneumonia following HSCT has not been well investigated.

By investigating the efficacy of MSC treatment for HSCT-related pneumonia via comparing the outcomes in patients with and without MSC treatment, this study will provide a promising therapy for HSCT-related pneumonia.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
1 Year to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patients with pneumonia after HSCT;
  • patients under the age of 18 years;
  • patients with normal pulmonary function before HSCT.

Exclusion Criteria

  • patients with other severe complications in progress when pneumonia occurred.

Outcomes

Primary Outcomes

overall cure rate

Time Frame: 12 months

the proportion of cured cases in all cases

time to cure

Time Frame: 12 months

the time from the first diagnosis of pneumonia to a cure was achieved

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Guangzhou Women and Children's Medical Center
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xu Yang

Principal Investigator

Guangzhou Women and Children's Medical Center

Study Sites (1)

Loading locations...

Similar Trials